JPS6139930B2 - - Google Patents
Info
- Publication number
- JPS6139930B2 JPS6139930B2 JP13256777A JP13256777A JPS6139930B2 JP S6139930 B2 JPS6139930 B2 JP S6139930B2 JP 13256777 A JP13256777 A JP 13256777A JP 13256777 A JP13256777 A JP 13256777A JP S6139930 B2 JPS6139930 B2 JP S6139930B2
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- reaction
- sodium
- interchain
- globulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010074605 gamma-Globulins Proteins 0.000 claims description 14
- -1 trithionate ion Chemical class 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 35
- 102000018358 immunoglobulin Human genes 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 24
- 238000000034 method Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 230000002391 anti-complement effect Effects 0.000 description 12
- 108010008730 anticomplement Proteins 0.000 description 12
- 239000002504 physiological saline solution Substances 0.000 description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- HAEPBEMBOAIUPN-UHFFFAOYSA-L sodium tetrathionate Chemical compound O.O.[Na+].[Na+].[O-]S(=O)(=O)SSS([O-])(=O)=O HAEPBEMBOAIUPN-UHFFFAOYSA-L 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- LSVVNVHHHMEPJZ-UHFFFAOYSA-L [Na+].[Na+].[O-]S(=O)(=O)SS([O-])(=O)=O Chemical compound [Na+].[Na+].[O-]S(=O)(=O)SS([O-])(=O)=O LSVVNVHHHMEPJZ-UHFFFAOYSA-L 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000010265 sodium sulphite Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000006277 sulfonation reaction Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- WAIZSJUARDIDFV-UHFFFAOYSA-L [K+].[K+].[O-]S(=O)(=O)SS([O-])(=O)=O Chemical compound [K+].[K+].[O-]S(=O)(=O)SS([O-])(=O)=O WAIZSJUARDIDFV-UHFFFAOYSA-L 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KRURGYOKPVLRHQ-UHFFFAOYSA-N trithionic acid Chemical compound OS(=O)(=O)SS(O)(=O)=O KRURGYOKPVLRHQ-UHFFFAOYSA-N 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13256777A JPS5467025A (en) | 1977-11-07 | 1977-11-07 | Preparation of immue gamma-globlin derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13256777A JPS5467025A (en) | 1977-11-07 | 1977-11-07 | Preparation of immue gamma-globlin derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5467025A JPS5467025A (en) | 1979-05-30 |
| JPS6139930B2 true JPS6139930B2 (enrdf_load_stackoverflow) | 1986-09-06 |
Family
ID=15084314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13256777A Granted JPS5467025A (en) | 1977-11-07 | 1977-11-07 | Preparation of immue gamma-globlin derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5467025A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0644671U (ja) * | 1991-02-13 | 1994-06-14 | 株式会社バンガード | 携帯用運搬車における支持体の解除装置 |
| JPH07165083A (ja) * | 1993-12-16 | 1995-06-27 | Murata Mach Ltd | 手押し台車 |
-
1977
- 1977-11-07 JP JP13256777A patent/JPS5467025A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0644671U (ja) * | 1991-02-13 | 1994-06-14 | 株式会社バンガード | 携帯用運搬車における支持体の解除装置 |
| JPH07165083A (ja) * | 1993-12-16 | 1995-06-27 | Murata Mach Ltd | 手押し台車 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5467025A (en) | 1979-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4347179A (en) | Process for the preparation of immunogammaglobulin using trithionate compounds | |
| US4340589A (en) | Antithrombin preparation and process for the production thereof | |
| FI66534C (fi) | Foerfarande foer framstaellning av immunoglobulin som innehaoller antikroppar och aer laempligt foer intravenoes administration | |
| US4168303A (en) | Lyophilized native gamma globulin preparation for intravenous administration | |
| US4960757A (en) | Pasteurized human fibrinogen (HF), a process for its preparation, and its use | |
| US4415553A (en) | Compositions, processes for their preparation and method for treatment of neoplasms | |
| RU2620072C2 (ru) | ПРОИЗВОДНЫЕ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ VII И VIIa, КОНЪЮГАТЫ И КОМПЛЕКСЫ, СОДЕРЖАЩИЕ ИХ, И ИХ ПРИМЕНЕНИЕ | |
| HU189469B (en) | Process for preparing antitumour immunoglobulin-derivatives with antibody effect, comprising ricin a subordinate unit | |
| DE3061547D1 (en) | Process of preparation of an intravenous immunoglobulin solution, containing concentrated igm | |
| US11560436B2 (en) | Anti-VWF D'D3 single-domain antibodies fuse to clotting factors | |
| PL99599B1 (pl) | Sposob otrzymywania tolerowanej srodzylnie gammaglobuliny | |
| EP0025321B1 (en) | Composition containing s-sulfonated immunoglobulin and aggregation preventing or aggregate dissociating agent therefor, and processes for preparing compositions containing high proportions of monomeric s-sulfonated immunoglobulin | |
| JPS6139930B2 (enrdf_load_stackoverflow) | ||
| JPS6136811B2 (enrdf_load_stackoverflow) | ||
| GB2032437A (en) | Method for the preparation of an immune globulin solution suitable for intravenous use | |
| CA1105383A (en) | Immunoglobulin having a reduced complement fixation, a process for its preparation and agents containing this immunoglobulin | |
| EP0041449B1 (fr) | Application d'une composition ophtalmique contenant un activateur du plasminogène, au nettoyage des lentilles cornéennes | |
| JPS6142558B2 (enrdf_load_stackoverflow) | ||
| JPS62886B2 (enrdf_load_stackoverflow) | ||
| US2446974A (en) | Synthesis of a penicillin-protein reaction product | |
| JPS6133805B2 (enrdf_load_stackoverflow) | ||
| JPS6155895B2 (enrdf_load_stackoverflow) | ||
| JPS6138171B2 (enrdf_load_stackoverflow) | ||
| SU1127525A3 (ru) | Способ выделени альбумина | |
| JPH0345080B2 (enrdf_load_stackoverflow) |